

INTRO

We are well into 2023 and are progressing with our plans. We have good made progress on our clinical trails, we are doing well with our manufacturing setup and we have outlined an updated business strategy.

Business Strategy

A pivotal-stage biotech company with a unique focus on children's medicine



- 1: Focused business model**
 - Targeting large unmet paediatric needs - in hospitals and emergency units
 - Repositioning existing medicine to fit children's needs - an accelerated and highly de-risked route-to-market approach
- 2: Pipeline delivering value**
 - CT001 - an analgesic nasal spray for acute painful procedures in children, based on >10 years of clinical experience
 - CT001 is in late-stage clinical development, final clinical results expected end 2023
- 3: Building a business**
 - Commercialization intended to be based on partnerships - aiming at generating a positive cash-flow trend faster
 - Supply and manufacturing are outsourced to leading expert companies in Europe

Focused business model: There is a large unmet need for acute pain treatment of children. An example is that off label use of medication is the rule rather than the exception and that 79% of the emergency rooms in Scandinavia use physical restraint on children. In Europe, an estimated 20 million children are exposed each year to acute and procedural pain. The number is similar for the US. EMA is addressing this paediatric need by offering companies a 10 years of market exclusivity, in exchange for developing evidence-based medicine for children.

Annual General Meeting

On March 23 2023, the Annual General Meeting was held, basically approving the Annual Report for 2022. Subsequently the Board of Directors appointed a new Chairman of the Board.

[Link to Summary](#)



Welcome to our new Chairman of the Board, Martin Olin

At the Annual General Meeting in March, a new chairman was elected.

- Martin Olin has been a member of the board of directors since 2020 is now chairman of the board
- Martin is CEO of BerGenBio and was previously CEO of Symphogen
- Adam Steensberg, the previous chairman of the board, will continue as board member.



Cessatech develops CT001, a nasal spray which is a needle-free administration when treating acute pain in children – this is an example of repositioning. Repositioning is a common way to develop and improve medical products. We use a nasal spray because it is easier to use for the medical personal but primarily because children generally prefer a nasal spray over a needle. Repositioning of medical products means that an existing product is re-developed and used in a new way.

The likelihood of success for a repurposed drug depends on several factors, such as the safety profile, efficacy in the new indication, and the size of the target patient population. In general, repurposed drugs have a higher likelihood of success than new drugs because they have already undergone some level of testing in humans and have an established safety profile. A recent study showed that repurposed drugs had a success rate of 30% compared to 10% for new drugs.

Repurposing existing drugs can be attractive as the process is often less risky, more cost effective and can be undertaken in less time.

Some very well-known examples of repurposing drugs are sildenafil (Viagra), Aspirin, Minoxidil (Rogaine), Zidovudine, Metformin...

LEAD ASSET CT001: AT LATE-STAGE DEVELOPMENT

Pipeline update

During 2023 we will give more updated on the remaining clinical trials and our accomplishments...



Teaching Old Drugs New Tricks
Gaps in paediatric therapeutics often result in off-label use and specifically, novel uses for existing medications, termed "drug repurposing."

[Read full article](#)



In 2022 the first patient was dosed in pivotal trial (0205) in adult patients - this trial investigates the postoperative analgesic efficacy of CT001.

[Find out more](#)

Financials including 2022 results

Income Statement ('000)	Q4'21	Q1'22	Q2'22	Q3'22	Balance Sheet ('000)	Q4'21	Q1'22	Q2'22	Q3'22
Operating expenses	3,426	2,205	2,473	2,297	Assets	30,653	24,648	22,323	20,047
Staff expenses	972	1,531	1,467	955	Cash	3,275	21,204	17,846	15,001
Loss before tax	4,402	3,811	3,994	3,292	Equity	26,242	23,392	20,228	17,744
Net loss	3,504	3,045	3,319	3,319	Solidity rate	86%	95%	91%	89%

Cessatech management team



Jes Trygved
CEO



Helle Sickmann Bendixen
CLINICAL



Martin Juhl
CMC & DEVICE




Louise Bak
REGULATORY LEAD

Shareholders

Management, Board of Directors and other Insiders.

Together currently hold 16%



	Use	Indication	Pre-clinical	Phase I	Phase II	Pivotal - Ph III
CT001	Fixed combination	Non-invasive nasal spray	Acute pain	CT001		
CT002	Sedative-analgesic	Non-invasive nasal spray	Sedation	CT002		
CT003	Local analgesia	Local gel	Topical anaesthesia	CT003		

THERE IS AN UNMET NEED FOR PAIN TREATMENT OF CHILDREN.

Studies show that of label use of medication is the rule rather than the exception and that 79% of the emergency rooms in Scandinavia use physical restraint on children.

Cessatech aims to meet that need – and the first product and lead asset, CT001, is a nasal spray for children aged 1–17 years that experience acute pain or pain related to medical procedures.

Drugs that are developed by Cessatech should be proven effective in adults and represent a medical unmet need in children where a good effect can be documented. Thus offering economic value creation by identifying and developing drugs with a short time to market and risk-reduced profile.

